socalTECH

OCTOBER 23, 2019

Thousand Oaks-based biotech giant Amgen said today that its CFO, David W. Meline, is planning to retire, serving as CFO through the end of 2019, but will remain at the company through the second quarter of 2020. Meline--who has been Executive Vice President and Chief Financial Officer at Amgen since 2014--will be replaced by Peter H.

Thousand Oaks 100

Thousand Oaks Equity Develop Development 100

socalTECH

NOVEMBER 7, 2013

Thousand Oaks-based ImmunGene , a startup biotech company developing antibody-based, protein therapeutics for treating cancer, said today that it has raised $9M in a Series A funding, to advance its early stage development products. According to the company, the funding came from Ally Bridge Group.

Thousand Oaks 164

Thousand Oaks UCLA Venture Capital Equity 164

socalTECH

SEPTEMBER 8, 2011

Thousand Oaks-based biotech giant Amgen has backed a developer of therapeutic antibodies, via its venture capital arm, Amgen Ventures. Theraclone is developing therapeutic antibodies for treating infectious disease and cancer. Theraclone is developing therapeutic antibodies for treating infectious disease and cancer.

Thousand Oaks 150

Thousand Oaks Venture Capital Equity Capital 150

socalTECH

JULY 2, 2010

Thousand Oaks-based Ceres , a developer of biofuel crop technology, has raised another $20M in funding, according to a regulatory filing from the firm Friday. Ceres has previously raised funds from Warburg Pincus, Soros Private Equity, QuestMark Partners, Oxford BioScience, Oppenheimer, Monsanto, KBC, H&Q, and GIMV.

Thousand Oaks 150

Thousand Oaks Equity Funding Capital 150

socalTECH

MAY 20, 2010

Thousand Oaks-based Ceres , a developer of biofuel crop technology, and Novozymes , a developer of enzymes, said today that the two have entered into a research collaboration around cellulosic biofuel production. Ceres is working on both crops to optimize the amount of sugar which can be used to produce biofuel.

Thousand Oaks 145

Thousand Oaks Equity Research Product 145

Xconomy

JULY 22, 2016

. —Celgene (NASDAQ: CELG ), of Summit, NJ, inked its latest immuno-oncology deal, forming a wide-ranging alliance with Cambridge-based Jounce Therapeutics to develop a group of cancer drugs. Also in Cambridge, Oncorus debuted with a $57 million round and a plan to develop next-gen oncolytic viruses, a type of cancer immunotherapy tool.

Startup 40

Startup San Diego News Thousand Oaks 40

Xconomy

JUNE 10, 2016

—More developments arrived this week in the Sarepta Therapeutics (NASDAQ: SRPT ) saga. —On the positive side, Thousand Oaks, CA-based Amgen (NASDAQ: AMGN ) released an overview of Phase 2 data that showed its migraine prevention drug, erenumab, is keeping pace with rival drugs in a heated race to market.

Incubator 67

Incubator Thousand Oaks Screening Pricing 67